JAVIER ZAMORA ROMERO-rekin lankidetzan egindako argitalpenak (8)

2021

  1. Anti-biofilm activity of murepavadin against cystic fibrosis Pseudomonas aeruginosa isolates

    Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 10, pp. 2578-2585

  2. Propensity-Score Analysis Reveals that Sex is Not a Prognostic Factor for Mortality in Intensive Care Unit-Admitted Patients with Septic Bacteremia

    International Journal of Infectious Diseases, Vol. 110, pp. 36-44

2020

  1. Long-term docosahexaenoic acid (DHA) supplementation in cystic fibrosis patients: a randomized, multi-center, double-blind, placebo-controlled trial

    Prostaglandins Leukotrienes and Essential Fatty Acids, Vol. 162

2016

  1. New Insights into the Enterococcus faecium and Streptococcus gallolyticus subsp. gallolyticus Host Interaction Mechanisms

    PloS one, Vol. 11, Núm. 7, pp. e0159159

2014

  1. Improvement of digestive health and reduction in proteobacterial populations in the gut microbiota of cystic fibrosis patients using a Lactobacillus reuteri probiotic preparation: A double blind prospective study

    Journal of Cystic Fibrosis, Vol. 13, Núm. 6, pp. 716-722

  2. Individual variability in finger-to-finger transmission efficiency of Enterococcus faecium clones

    MicrobiologyOpen, Vol. 3, Núm. 1, pp. 128-132

2013

  1. In Vitro activity of fosfomycin against a collection of clinical Pseudomonas aeruginosa isolates from 16 spanish hospitals: Establishing the validity of standard broth microdilution as susceptibility testing method

    Antimicrobial Agents and Chemotherapy, Vol. 57, Núm. 11, pp. 5701-5703

2011

  1. Stationary biofilm growth normalizes mutation frequencies and mutant prevention concentrations in Pseudomonas aeruginosa from cystic fibrosis patients

    Clinical Microbiology and Infection, Vol. 17, Núm. 5, pp. 704-711